Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Learning the Language of Microbiological Control

Key Terms for Water Treatment Novices Water treatment specialists can forget that their clients may not understand the technical terms used in our industry. The language of microbiological control can be particularly confusing. To help establish a common working vocabulary, it’s important to define some key terms. Let’s get started! Types of Microorganisms Microorganisms are living…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Key Terms for Water Treatment Novices

Water treatment specialists can forget that their clients may not understand the technical terms used in our industry. The language of microbiological control can be particularly confusing. To help establish a common working vocabulary, it’s important to define some key terms. Let’s get started!

Types of Microorganisms

Microorganisms are living organisms that require high magnification to see because they are so small.

Bacteria are single cell microorganisms that require water, but not light, for normal grow. They are so small (0.5 to 5.0 micron) that it would take 200,000 to two million bacteria placed end to end to measure a yard. Under ideal conditions, bacteria populations can double every 15 minutes. There are over 10,000 distinct species of bacteria, many of which can cause serious problems in water systems.

Aerobic bacteria require oxygen for growth. Many types of aerobic bacteria can form thick, sticky biofouling deposits that can block water flow, reduce heat transfer, increase pumping costs, cause corrosion, and increase the potential for disease. These deposits are generically called slime, and result from bacteria forming protective biofilms on system surfaces.

Anaerobic bacteria require an absence of oxygen for growth. They can often be found growing underneath biofilms and biofouling deposits. Anaerobic bacteria including Sulfate Reducing Bacteria (SRB) are a major cause of microbiologically influenced corrosion (MIC) in water systems. Many anaerobic bacteria produce spores as a survival mechanism and can be cultivated from oxygenated water.

Protozoa are single cell microorganisms that can move independently, and feed on biofilm associated bacteria and waste products. Amoebae are a type of protozoa. Although microscopic, protozoa are typically 5 to 100 times larger than bacteria. The presence of protozoa in a water system indicates advanced microbiological growth associated with biofilms.

Legionella is a common waterborne bacteria that can cause a serious, sometimes fatal illness called Legionnaires’ disease in exposed individuals. It is caused by inhaling aerosolized droplets of water containing an infectious amount of Legionella bacteria. It is characterized by fever, chills, lung congestion, and severe pneumonia. The elderly, sick, immunocompromised, and smokers are most susceptible to develop Legionnaires disease upon exposure. Over 50 different species of Legionella have been identified. Only about half of the species have been associated with disease,

Colonization Characteristics

Microorganisms can be classified based on their colonization characteristics:

Planktonic bacteria are “free floating” in the bulk system water. Whether performed in a laboratory or in the field using dip slides, bacteria culture tests on water samples only measure planktonic bacteria counts.

Sessile bacteria are “surface attached” associated with biofilm deposits. Sessile bacteria are not detected by bulk water bacteria counts.

Biofilms are complex communities of surface attached bacteria growing inside a protective microbial secretion often called slime. Although biofilms start out microscopic in size, they can grow into visible biofouling deposits in just a matter of days. A wide range of problem causing microorganisms can grow to high levels protected within biofilms and associated microorganisms, especially amoebae. Once established, biofilms are difficult to remove and kill.

Extracellular Polymeric Substances (EPS) are microbial secretions that establish the foundation for biofilms and biofouling deposits. EPS secretions tightly bind biofilms to systems surfaces and protect growing microorganisms from environmental hazards including high level cleaner and biocide additions.

Biocides Types

Oxidizing biocides kill or inhibit bacteria growth by physically destroying cell structures. Chemical compounds that fall into this category are chlorine, bromine and peroxide.

Non-oxidizing biocides kill bacteria by interfering with essential metabolic processes, in effect poisoning the bacteria. Some common non-oxidizing biocides are glutaraldehyde and isothiazolin.

Sanitize, Disinfect, or Sterilize?

Although the exact definition will vary depending on the application, these terms refer to the relative effectiveness of processes for eradicating harmful microorganisms. The lowest level of cleaning and microbial control is sanitizing, following by disinfection, and then sterilization.

  • Sanitizing involves physical and chemical cleaning processes that reduce the number of microorganisms.
  • Disinfection involves adding disinfection chemicals in low-level, intermediate level or high-level control strategies.
  • Sterilization involves using chemicals, temperature, gas and/or pressure to kill or inactivate all disease-causing bacteria, spores, fungi and viruses

The First Step in Problem Solving

Understanding the terms used in the water treatment industry is always the first step in proper problem solving. Everyone working together on a problem must have the same basic knowledge of terms used in describing the conditions and the appropriate corrective tools. We will then be in a better position to achieve our common goal of maintaining clean cooling water systems that are free from uncontrolled microbiological growth.

Chem-Aqua provides custom water treatment solutions. We specialize in providing custom designed water treatment programs for boiler, cooling, and process water systems. We help our customers minimize their energy, water, and maintenance costs while ensuring safe and reliable operation of these critical systems.

Read more at chemaqua.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512